gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Protein Microarrays in Tumour Diagnosis

Meeting Abstract

Suche in Medline nach

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocIS109

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk109.shtml

Veröffentlicht: 20. März 2006

© 2006 Wingren.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Protein microarrays, and in particular antibody-based microarrays, are among the novel class of rapidly evolving proteomic technologies that holds great promise in biomedicine. Miniaturized microarrays (< 1 cm2) can be printed with thousands of e.g. individual antibodies carrying the desired specificities, and with biological sample (e.g. an entire proteome) added, virtually any specifically bound analytes can be detected. While consuming only minute amounts (> pL scale) of the reagents, ultra-sensitive assays (zeptomol range) can readily be performed in a highly multiplexed manner. The microarray patterns generated can then be transformed into proteomic maps, or detailed molecular fingerprints, revealing the composition of the proteome. Thus, protein expression profiling and global proteome analysis using this tool will offer new opportunities for cancer (disease) diagnostics, drug target and biomarker discovery, and insights into cancer (disease) biology. Adopting the antibody (protein) microarray technology platform, several biomedical applications, ranging from focused assays to semi proteome-scale analysis are rapidly emerging, especially within cancer proteomics. To date, major efforts have been placed upon detecting novel cancer biomarkers and differentially expressed set of proteins (i.e. cancer specific protein signatures) with a tremendous potential within cancer diagnostics. In our laboratory, we have successfully developed a high-performing antibody microarray technology platform based on recombinant antibody fragments with the long-term goal to perform high-throughput cancer proteomics. In this presentation, I will present the current status of the antibody (protein) microarray technology and its current and future biomedical applications, with a particular focus on cancer proteomics and tumour diagnosis.


References

1.
Wingren C, Borrebaeck CAK. High-throughput proteomics using antibody microarrays. Expert Rew Proteomics. 2004;1:358-64.